SEC Filing Summary: SRx Health Solutions, Inc. (SRXH)
Business Context and Reporting Period
This Form 8-K Current Report was filed by SRx Health Solutions, Inc. on February 20, 2026, regarding events occurring on February 18, 2026. The Company is incorporated in Delaware and its common stock trades on the NYSE American under the symbol "SRXH". The filing addresses a regulatory compliance issue with the New York Stock Exchange (NYSE) regarding the listing of newly issued shares.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and listing compliance matters.
Material Changes and Events
- NYSE Warning Letter: On February 18, 2026, the Company received a public warning letter from the NYSE Regulation Staff for failing to comply with Sections 301 and 713 of the NYSE American LLC Company Guide.
- Issuance Details: The violation concerns the issuance of approximately 7.5 million shares of Common Stock between December 31, 2025, and January 23, 2026. These shares were issued upon the conversion of Series A Convertible Preferred Stock.
- Compliance Failures:
- Section 301: The Company failed to file an application for listing approval for the additional shares prior to issuance, despite filing an application on December 12, 2025, before conversion conditions were met.
- Section 713: The Company failed to obtain valid stockholder approval for an issuance exceeding 20% of outstanding Common Stock. Although stockholders approved the issuance via written consent on October 8, 2025, the NYSE deemed this approval deficient under internal guidance regarding generic proxy proposals.
- Current Status: As of the filing date, all Series A Convertible Preferred Shares have been either converted into Common Stock or redeemed by the Company. No Preferred Shares remain outstanding.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or management commentary on future operations. The primary risk identified is the Company's failure to satisfy continued listing rules, which could potentially impact the trading status of its securities if not resolved. The Company has attached the Warning Letter and a press release as exhibits to this filing.
Investor Verification Checklist
- Verify the Company's current listing status on the NYSE American following the receipt of the Warning Letter.
- Review the Company's Definitive Schedule 14C (filed October 20, 2025) to understand the specific stockholder consent process that was deemed deficient.
- Confirm the total number of outstanding Common Stock shares post-conversion to assess the dilution impact of the 7.5 million shares issued.
- Monitor for any subsequent filings regarding the Company's plan to regain compliance with NYSE listing standards.